Light Mode
$248.24 ↑ +0.00 (+0.00%) Trading Up from the previous close of $248.24, $0.73 below the day’s high of $248.97
+20.40 (+8.95%) / 6M
Momentum, market sentiment, and recent alerts
JAZZ reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +81.6%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.